Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of lyophilized recombinant human brain natriuretic peptide in acute heart failure
CTR20255143Phase 3Active
- Sponsor
- Shijiazhuang Wotai Biotechnology
- Start
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Acute Heart Failure (AHF) comparing Lyophilized recombinant human brain natriuretic peptide with Placebo (2 arms). Primary endpoint: Proportion of subjects with self-reported dyspnea improvement compared with baseline. Started Jan 2026; status: active.
02
Drugs
nesiritide
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on CTR20255143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255143.